Author:
Zhang Xin,Yao Yu,Zhou Nan
Publisher
Springer Nature Singapore
Reference21 articles.
1. Balana C, Barroso CM, Del Barco Berron S, et al. Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: a Spanish research group in neuro-oncology (GEINO) trial. J Clin Oncol. 2019;37(15_suppl):2001.
2. Bell EH, Won M, Fleming JL, et al. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG J 9802. Clin Oncol. 2019;37(15_suppl):2002.
3. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77.
4. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG J 9402. Clin Oncol. 2013;31(3):337–43.
5. Chan AK, Yao Y, Zhang Z, et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2015;28(2):177–86.